Characterization of bone metastases from rapid autopsies of prostate cancer patients

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 3924-3932

  Mehra, Rohit ^a   Kumar Sinha, Chandan ^a   Shankar, Sunita ^a   Lonigro, Robert J ^a   Jing, Xiaojun ^a   Philips, Neena E ^a   Siddiqui, Javed ^a   Han, Bo ^a   Cao, Xuhong ^a   Smith, David C ^a   Shah, Rajal B ^b   Chinnaiyan, Arul M ^a   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CARIS LIFE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CADHERIN; CHEMOKINE RECEPTOR CXCR; COMPLEMENTARY DNA; CYSTEINE RICH TRANSMEMBRANE BONE MORPHOGENIC PROTEIN REGULATOR 1; DICER; DNA; MATRIX METALLOPROTEINASE; NEGATIVE ELONGATION FACTOR; PEPTIDASE; REGULATOR PROTEIN; REPRESSOR PROTEIN; RNA; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR EZH2; UBIQUITIN SPECIFIC PEPTIDASE 10; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOPSY; BMP GENE; BONE METASTASIS; CDH17 GENE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CRIM1 GENE; CXCR GENE; EZH2 GENE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IGFBP2 GENE; MALE; METHODOLOGY; MICROARRAY ANALYSIS; MMP GENE; NELF GENE; PCDH11X GENE; PCDH15 GENE; PCDHGA5 GENE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; RNA EXTRACTION; SDF1 GENE; USP10 GENE; WHSC1 GENE; WHSC2 GENE;

AGED; AUTOPSY; BONE AND BONES; BONE NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 79959249179     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3120     Document Type: Article

References (29)

1. Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. J Clin Invest 2007;117:2351-61. (Pubitemid 47494332)
2. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
4. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70. (Pubitemid 34289218)
5. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008;68:3584-90.
6. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006;8:578-86. (Pubitemid 44061313)
7. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16. (Pubitemid 39665537)
8. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000;6:1038-45. (Pubitemid 30159365)
9. Suprun H, Rywlin AM. Metastatic carcinoma in histologic sections of aspirated bone marrow: a comparative autopsy study. South Med J 1976;69:438-9.
10. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-53. (Pubitemid 36875509)
11. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
12. Seshan VE, Olshen A. DNAcopy: DNA copy number data analysis R package version 1.22.1. [cited2010 Dec 10]. Available from: http://www.bioconductor.org/ packages/2.3/bioc/html/DNAcopy.html.
13. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
14. Dabney A, Storey J, Warnes G. qvalue: Q-value estimation for false discovery rate control R package version 1.24.0. [cited 2010 Dec 10]. Available from:http://CRAN.R-project.org/package=qvalue.
15. Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 2007;22:1129-47. (Pubitemid 47470307)
16. Mariotti M, Manganini M, Maier JA. Modulation of WHSC2 expression in human endothelial cells. FEBS Lett 2000;487:166-70. (Pubitemid 32057106)
17. Kassambara A, Klein B, Moreaux J. MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun 2009;379:840-5.
18. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t (4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-34. (Pubitemid 28492306)
19. Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G. Down-regulation of dicer expression in ovarian cancer tissues. Clin Biochem 2010;43:324-7.
20. Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y, et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009;136:2304- 15.e1-4.
21. Zheng ZH, Sun XJ, Fu WN, Guan Y, Gao F, Wang Y, et al. Decreased expression of DICER1 in gastric cancer. Chin Med J 2007;120:2099-104. (Pubitemid 350268157)
22. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006;169:1812-20. (Pubitemid 351182010)
23. Reddy SD, Gajula RP, Pakala SB, Kumar R. MicroRNAs and cancer therapy: the next wave or here to stay?Cancer Biol Ther 2010;9:479-82.
24. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010;140:384-96.
25. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, et al. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 2007;13:3244-9. (Pubitemid 46944908)
26. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 2008;68:5785-94.
27. Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001;61:6372-6.
28. Vincent-Salomon A, Bidard FC, Pierga JY. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J Clin Pathol 2008;61:570-6. (Pubitemid 351678207)
29. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008;14:5013-21.